Seeking Alpha
 

Roche Holding Ltd ADR (RHHBY)

- OTCQX
  • Thu, Jul. 23, 9:46 AM
    • Roche (OTCQX:RHHBY +0.8%) Q2 results (CHFm): Total Revenues: 11,752 (+2.4%); Pharmaceuticals: 9,028 (+2.7%); Diagnostics: 2,724 (+1.5%).
    • Key Product Sales: MabThera/Rituxan: 1,752 (+3.5%); Avastin: 1,644 (+7.3%); Herceptin: 1,613 (+3.7%); Lucentis: 375 (-10.9%); Actemra/RoActemra: 341 (+15.6%); Perjeta: 337 (+60.5%); Tarceva: 307 (-11.5%).
    • 2015 Guidance: Sales growth: low-to-mid single digit (unch); Core earnings growth: ahead of sales growth (unch).
    | Thu, Jul. 23, 9:46 AM | Comment!
  • Wed, Apr. 22, 7:30 AM
    • Roche (OTCQX:RHHBY) Q1 results (CHFm): Total Revenues: 11,833 (+2.9%); Pharmaceuticals: 9,322 (+3.1%), U.S.: 4,392 (+13.4%), Europe: 2,178 (-10.2%), Japan: 763 (-9.7%), International: 1,989 (+4.8%); Diagnostics: 2,511 (+2.2%).
    • Product sales leaders: MabThera/Rituxan: 1,744 (+4.6%); Herceptin: 1,652 (+8.3%); Avastin: 1,619 (+3.5%); Lucentis: 394 (-3.2%); Actemra/RoActemra: 334 (+22.3%); Perjeta: 322 (+80.9%); Xolair: 281 (+37.1%).
    | Wed, Apr. 22, 7:30 AM | Comment!
  • Wed, Jan. 28, 7:31 AM
    • Roche (OTCQX:RHHBY) Q4 results (CHFm): Total Revenues: 12,705 (+6.6%); Pharmaceuticals: 9,731 (+6.8%), Diagnostics: 2,974 (+6.3%).
    • Pharmaceuticals: U.S.: 4,294 (+17.1%), Europe: 2,352 (+2.2%); Japan: 895 (-2.0%); International: 2,190 (-1.8%).
    • Sales By Product: MabThera/Rituxan: 1,776 (+1.8%), Avastin: 1,668 (+8.0%), Herceptin: 1,596 (+7.5%), Lucentis: 441 (+0.7%), Tarceva: 321 (0.0%), Actemra/RoActemra: 327 (+19.3%), Pegasys: 204 (-28.4%), Xolair: 507 (+153.5%), Perjeta: 285 (103.6%), Xeloda: 153 (-55.7%).
    | Wed, Jan. 28, 7:31 AM | Comment!
  • Wed, Jan. 28, 3:23 AM
    • Missing analysts’ forecasts, Roche (OTCQX:RHHBY) said net income attributable to shareholders fell to 9.33B francs ($10.34B) from 11.16B francs a year earlier, despite rising sales of its cancer treatments.
    • The company said it was hit by impairments, restructuring costs and debt restructuring.
    • Roche expects sales this year to grow in low-to-mid single digits range, while core earnings per share should grow more than sales.
    • Roche shares are down 1.3% in Switzerland.
    | Wed, Jan. 28, 3:23 AM | Comment!
  • Dec. 29, 2014, 7:01 AM
    | Dec. 29, 2014, 7:01 AM | Comment!
  • Oct. 16, 2014, 9:29 AM
    • Roche (OTCQX:RHHBY) financial results ytd through Q3 (Millions of CHF): Group Sales: 34,757 (-0.3%); Pharmaceuticals: 26,965 (-0.8%), U.S. Pharma: 11,528 (+0.9%), Europe Pharma: 7,070 (+1.7%), Japan Pharma: 2,406 (-3.5%), International Pharma: 5,961 (-5.6%); Diagnostics: 7,792 (+1.5%).
    • 2014 Guidance: Group sales growth: low-to-mid-single digit; Core EPS growth: >Group sales growth; Dividend outlook: further increase.
    | Oct. 16, 2014, 9:29 AM | Comment!
  • Oct. 9, 2014, 11:31 AM
    • Roche (OTCQX:RHHBY -1.5%) will report Q3 results on October 16 at 7:00 am CEST/1:00 am ET/10:00 pm PT (evening before). The conference call will begin at 2:00 pm CEST/8:00 am ET/5:00 am PT.
    | Oct. 9, 2014, 11:31 AM | Comment!
  • Jul. 24, 2014, 6:42 AM
    • Roche (OTCQX:RHHBY) 1H results (CHF M): Group Sales: 22,974 (-1.4%); Pharmaceuticals: 17,834 (-1.8%); Diagnostics: 5,140 (+0.1%); Core Operating Profit: 9,410 (-0.8%); CF Ops: 7,869 (+5.7%); Net Income: 5,641 (-6.7%); EPS: 7.57 (-0.1%).
    • Product sales growth: Herceptin: +6%; Avastin: +6%; Lucentis: +6%; Actemra/RoActemra: +22%; Zelboraf: -5%; MabThera/Rituxan: +4%; Perjeta: +276%; Kadcyla: +188%; Xeloda: -34%.
    • 2014 Guidance: Group sales growth: low- to mid-single digit; Core EPS: >sales growth; Dividend: increase.
    | Jul. 24, 2014, 6:42 AM | Comment!
  • May 12, 2014, 9:02 AM
    • Inovio (INO) revenues: $1.4M vs $14.3K; net loss: ($108M) (-21.3%); loss/share: ($0.05) (+16.7%); quick assets (ex-A/R): $116.8M (+122.1%).
    • Capital position should be sufficient to fund the firm's operations through 2017.
    • Management expects to report data on the Phase 2 trial for VGX-3100, SynCon immunotherapy against HPV-caused cancers and pre-cancers delivered with the Cellectra electroporation device by mid-year.
    • INO-5150 cancer immunotherapy Phase 1 trial to be launched in Q3. This will trigger a milestone payment from partner Roche (RHHBY). 
       
    | May 12, 2014, 9:02 AM | 4 Comments
  • Jan. 30, 2014, 2:17 AM
    • Roche's (RHHBF) 2013 net profit rose 18% to 11.4B Swiss francs ($12.7B), missing expectations of 11.62B francs.
    • Core EPS +10% to 14.27 francs, falling short of consensus of 14.78 francs.
    • Sales +3% to 46.8B francs topping estimates of 46.7B francs.
    • Earnings were boosted by sales of Roche's oncology, immunology and ophthalmology products, as well as of its diagnostic offerings.
    • Roche plans to increase its dividend by 6% to 7.80 francs a share.
    • Roche forecasts that 2014 revenue will rise by a low- to mid-single-digit percentage at constant currencies and that core EPS will grow at a faster rate, with earnings boosted by sales of its biggest cancer drugs and new products. Kadcyla (breast cancer) and Gazyva (leukemia) were authorized in the U.S. last year. (PR)
    | Jan. 30, 2014, 2:17 AM | Comment!
  • Oct. 17, 2013, 4:02 AM
    • Roche's (RHHBY.OB) Pharmaceutical sales +2.7% to 9.03B Swiss francs ($9.9B); diagnostics division +2.5% to 2.54B francs.
    • Expects full-year sales to rise in line with 2012, when revenues climbed 7%. Expects EPS to increase faster than revenues.
    • In nine-month period, Roche's HER2 breast-cancer franchise, Avastin and Actemra/RoActemra helped boost sales.
    • The main regional growth drivers this year have been the U.S., where nine-month sales rose 12%, and key emerging markets (especially China), where revenue climbed 10%.
    • "I am very encouraged by the uptake of our new cancer medicines, Perjeta and Kadcyla, which significantly improve the survival rates of patients with a very aggressive form of breast cancer," says CEO Severin Schwan.
    • Roche expects to further increase its dividend this year. (Previous) (PR)
    | Oct. 17, 2013, 4:02 AM | Comment!
  • Oct. 17, 2013, 2:13 AM
    • Roche's (RHHBY.OB) Q3 revenues +8% to 11.57B Swiss francs ($12.63B), just above consensus of 11.54B francs.
    • Confirms full year outlook. (PR)
    | Oct. 17, 2013, 2:13 AM | Comment!
  • Sep. 9, 2013, 8:55 AM
    • PDL BioPharma (PDLI) expects Q3 revenue of $97M, up 14% on year but a bit below consensus of 97.91M.
    • PDL made the projection based on increased Q2 sales of several drugs for which PDL is due to receive royalties in Q3, including Avastin, Herceptin and Lucentis.
    • PDL will receive the payments for many of the drugs from Roche unit Genentech (RHHBY.OB). (PR)
    | Sep. 9, 2013, 8:55 AM | Comment!
  • Apr. 11, 2013, 3:13 AM
    Roche (RHHBY.OB): Q1 sales +5.1% to 11.6B Swiss francs ($12.4B), above consensus of 11.5B francs. Pharmaceuticals sales +7% to 9.2B francs, diagnostics +1% to 2.4B francs; Herceptin (breast cancer) 1.57B francs; Tamiflu +84% to 335M francs, due to severe flu season in U.S. Reiterates that 2013 sales will rise at same rate as in 2012, while core EPS will increase faster than revenues. (PR)
    | Apr. 11, 2013, 3:13 AM | Comment!
  • Jan. 30, 2013, 3:04 AM
    Roche Holdings (RHHBY.OB): 2012 net profit +2.4% to 9.77B francs ($10.6B). Core EPS +11% to 13.62 vs consensus of 13.60. Sales +7% to 45.5B francs. Earnings boosted by breast cancer treatment Perjeta and the weakening of the Swiss franc vs the dollar and the yen. Declares dividend of 7.35 francs/share vs 6.80 francs a year ago. Expects revenue to grow in line with 2012 but core EPS to grow faster, and to again increase its dividend. (PR)
    | Jan. 30, 2013, 3:04 AM | Comment!
  • Oct. 16, 2012, 3:09 AM
    Roche Holdings (RHHBF.PK): Q3 revenues +15% to 11.27B francs ($12.07B) vs consensus of 11.12B francs. Doesn't provide profit figures. Sales boosted by a weaker franc and growth in cancer medicines, although eye drug Lucentis declined due to competition. Reiterates FY outlook: sales growth in low-to-mid single digits, core earnings in high single-digits. Roche still wants to expand in gene sequencing despite failure of Illumina bid and is looking at deals. (PR)
    | Oct. 16, 2012, 3:09 AM | Comment!
Visit Seeking Alpha's
RHHBY vs. ETF Alternatives
Company Description
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and... More
Sector: Healthcare
Country: Switzerland